A randomized, phase II study of GW786034 (pazopanib) in stage D0 relapsed androgen sensitive prostate cancer following limited GnRH [gonadotropin-releasing hormone] agonist therapy.
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Pazopanib (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 01 Mar 2012 Results published in Prostate Cancer and Prostatic Diseases.
- 16 Aug 2011 Actual end date (December 2010) added as reported by ClinicalTrials.gov.
- 16 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.